Sval

Sval was paid $35K by Medicaid between Jul 2019 and Jul 2023, across 39 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 33% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#197 of 436

Median peer was paid$17K

This provider vs. median2.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	400	$0.00
2020	985	$0.00
2021	4,631	$8K
2022	4,068	$18K
2023	8,058	$9K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	33%	511	410	$12K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	25%	7,317	7,288	$9K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	16%	1,019	698	$6K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	10%	509	409	$4K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	6.0%	449	328	$2K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	3.5%	2,035	1,934	$1K
86328		2.7%	86	78	$960.01
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	2.6%	44	36	$910.34
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	2,048	1,968	$173.96
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	0%	196	192	$0.00
81400		0%	53	53	$0.00
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	0%	324	308	$0.00

27 more codes

81230		0%	53	$0.00
87640		0%	324	$0.00
87500		0%	324	$0.00
81240		0%	53	$0.00
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	0%	105	$0.00
81226		0%	53	$0.00
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	0%	324	$0.00
81227		0%	53	$0.00
81350		0%	53	$0.00
81306		0%	53	$0.00
81225		0%	53	$0.00
81231		0%	53	$0.00
81328		0%	53	$0.00
87653		0%	324	$0.00
81291		0%	53	$0.00
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	0%	324	$0.00
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	0%	324	$0.00
81241		0%	53	$0.00
81401		0%	56	$0.00
81335		0%	53	$0.00
87481		0%	324	$0.00
81232		0%	53	$0.00
87641		0%	324	$0.00
81249		0%	22	$0.00
81355		0%	22	$0.00
81408		0%	43	$0.00
81381		0%	22	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFERGUSUN, STEPHEN (OWNER)